SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Roche Holding AG RHHVF OTC

Other OTC • Healthcare • Drug Manufacturers - General • CH • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Roche Holding AG (RHHVF) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $403.29. It has a SharesGrow Score of 67/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Financials: revenue is $61.5B, -0.9%/yr average growth. Net income is $12.9B, growing at +6.7%/yr. Net profit margin is 20.9% (strong). Gross margin is 72.9% (+5.1 pp trend).

Balance sheet: total debt is $34.5B against $33.8B equity (Debt-to-Equity (D/E) ratio 1.02, moderate). Current ratio is 1.38 (adequate). Debt-to-assets is 34.2%. Total assets: $100.8B.

Analyst outlook: 3 / 9 analysts rate RHHVF as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 40/100 (Partial), Past 100/100 (Pass), Health 67/100 (Partial), Moat 94/100 (Pass), Future 20/100 (Fail), Income 85/100 (Pass).

RHHVF SharesGrow Score Overview

67/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 60/100

Valuation — P/E, PEG, Forward PEG

GROWTH 40/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 94/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 85/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RHHVF

RHHVF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

RHHVF: -0.9%/yr revenue is, +6.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

RHHVF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet RHHVF: Debt-to-Equity (D/E) ratio 1.02 (moderate), Current ratio is 1.38 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

RHHVF: Gross margin is 72.9% (+5.1 pp trend), $321B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 94/100. ≥ 70 = Pass.

View details →

Analyst outlook: 3 / 9 analysts rate RHHVF as buy (33%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

RHHVF: Net profit margin is 20.9%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range277-490.33

Volume2

Avg Volume (30D)27.56K

Market Cap$321.02B

Beta (1Y)0.33

Dividend Yield$12.4676

Share Statistics

EPS (TTM)16.19

Shares Outstanding$796M

IPO Date2009-02-13

Employees103,249

CEOThomas Schinecker

Financial Highlights & Ratios

Revenue (TTM)$61.55B

Gross Profit$44.89B

EBITDA$22.67B

Net Income$12.89B

Operating Income$16.37B

Total Cash$15.48B

Total Debt$34.45B

Net Debt$28.87B

Total Assets$100.75B

Price / Earnings (P/E)24.9

Price / Sales (P/S)5.22

Analyst Forecast

Rating ConsensusHold

Analysts Covering9

Buy 33% Hold 56% Sell 11%

Company Info

CountryCH

ExchangeOther OTC

CurrencyUSD

ISINCH1499059983

Price Chart

RHHVF

Roche Holding AG ↗ · Other OTC

Healthcare • Drug Manufacturers - General

277.00 52WK RANGE 490.33

People Also View

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

AstraZeneca PLC

Bristol-Myers Squibb Company

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message